Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Published Date: 18 Feb 2023

Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For relapsed or resistant DLBCL, odronextamab produced positive results.

2.

Study sets benchmark for treatment of advanced cervical cancer

3.

Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy

4.

Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.

5.

Early cancer detection during pregnancy and the postpartum period may be aided by breast milk examination.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot